Company intelligence / Profile preview

JAFCO Group

Ownership: Public · 8595
Development stage: Other

Overview

JAFCO Group is Japan’s largest and one of Asia’s leading venture capital and private equity firms. It invests in early-stage and growth-stage companies across IT services, healthcare & biotechnology, electronics, manufacturing, media, retail and other sectors in Japan, the U.S., and Asia. The group manages multiple funds totaling over ¥800 billion (~$7–8 billion) in assets under management as of 2023. Its investments have supported more than 1,000 IPOs globally. In healthcare/life sciences specifically, JAFCO has invested in cell therapy CDMOs and biotechs developing novel therapies.

Industry: Investors

Partnerships

As a VC/PE fund manager rather than operator/developer itself; partnerships are typically with limited partners/investors rather than pharma co-development deals.

Beyond the preview

Go deeper on JAFCO Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JAFCO Group.

Explore the full profile